Nasal Drug Delivery Technology Market – By Product Type, By Container Type, By Application, By Distribution Channel, By End Use – Global Forecast, 2024 to 2032

Nasal Drug Delivery Technology Market Size

The global nasal drug delivery technology market size was valued at USD 71.9 billion in 2023 and is estimated to grow at 6.8% CAGR from 2024 to 2032. Nasal drug delivery technology refers to the preparation, methods and systems meant for administration of drugs or medications through the nasal cavity. This technique helps in rapid absorption of drugs from the nasal mucosa into blood circulation. Nasal route is harnessed in medicine due to its advantages such as rapid onset of actions which is important for some conditions such as respiratory, pain and some neurological diseases.
 

Nasal drug delivery technology has gained importance in the field of pharmaceuticals as it enables localized as well as systemic effects without significant invasive methods. This method takes advantage of the large surface area of the nasal cavity and its rich blood supply for rapid absorption. Additionally, it does not suffer the first pass metabolism of the liver, which makes a huge difference in how stable and effective a drug is able to be. Stability and effectiveness is especially important. Nasal delivery systems are designed for not only rapid absorption but with the expectation of extremely high bioavailability for small molecules and drugs such as those acting on central nervous system (CNS). This feature is particularly useful for treatment of CNS disorders where rapid or targeted delivery to the brain is necessary.

The growing prevalence of chronic respiratory diseases, allergies, migraine, and other neurological diseases has created a market for nasal delivery systems. For instance, according to the Centers for Disease Control and Prevention (CDC), a rise in asthma in adults was reported from 6.9% in 2001 to 8% in 2021. Nasal drug delivery systems are especially important in asthma management because they are commonly used in fast or frequent administering methods. The escalation of the aforementioned health problems will most likely continue driving an increase in the demand for nasal drug delivery devices, hence improving the market growth.
 

Nasal Drug Delivery Technology Market Trends

• There is an expansion of nasal delivery devices design into new niches such as hormone delivery, the delivery of insulin, and those directed to the central nervous system. This extension does not only promote market growth, but it also increases the range of nasal drug delivery. With more research, these systems might be useful for solving complex health problems, leading to better results for patients and improving their quality of life.
   
• Additionally, combining nasal drug delivery systems with nanotechnology enables the effective delivery of high molecular weight drugs, peptide and protein medications through nanocarriers such as liposomes and chitosan-based nanoparticles. These nanocarriers increase drug stability and absorption through the nasal mucosa.
   
• Furthermore, the development of technology on devices has improved nasal drug delivery systems. The introduction of technologies such as pressurized metered dose inhalers and dry powder inhalers and unit dose devices has brought better dose accuracy, improved control, and greater patient compliance making nasal drug delivery systems more efficient and easier to use.
   

Nasal Drug Delivery Technology Market Analysis

The market is segmented into sprays, drops and liquids, gels, and powders. The sprays segment dominated the market with the largest revenue of USD 30.8 billion in 2023.
 

• Nasal sprays allow easy and quick absorption of drugs through the nose which brings faster therapeutic effects. This property is useful especially in cases of emergency medications such as relief from pain, allergy, and respiratory distress asthma attacks.
   
• There is an increase in numbers of allergy patients, asthma, and other respiratory disorders that require effective treatment. For instance, according to the American College of Allergy, Asthma and Immunology, approximately 7.7% or 24.9 million of U.S. individuals are affected by asthma, among whom approximately 20.2 million are adults and 4.6 million are children.
   
• Nasal sprays are the most preferred forms of drug delivery for antihistamines, corticosteroids, and decongestants; thus, they are very important for the management of such conditions. Their popularity reveals the key role of nasal sprays in most respiratory ailments.
   
• The lack of pain associated with nasal sprays enhances patient satisfaction and their willingness to use them. It is especially beneficial for patients suffering from chronic diseases as self-administration of nasal sprays is way easier than injections.
   
• The National Institutes of Health (NIH) has observed that intranasal drug delivery has the potential to increase medication adherence among specific patient groups, which can result in improved health management. This benefit makes nasal sprays particularly valuable in the context of long-term disease management.
   
• Therefore, the aforementioned factors are likely to sustain the demand for standard formulas in the near future.

Based on container type, the nasal drug delivery technology market is bifurcated into pressurized containers and non-pressurized containers. The non-pressurized containers segment dominated the market with the largest revenue share of 82.2% in 2023.
 

• Containers without internal pressure are simple and convenient for patients to use, especially during the self-medication process. This convenience encourages medication compliance, especially for patients suffering from chronic diseases and are on constant medication.
   
• Containers without internal pressure are created with the possibility of containing different types of formulations including liquids and suspensions. This allows for a wide range of nasal products which include antihistamines and saline solutions.
   
• Increase in availability of OTC nasal sprays and drops in non-pressure containers propels market growth too. These products are easily accessible for treatment of common ailments like allergies and nasal congestion, hence can be used by a larger segment of the population.
   
• Therefore, the aforementioned factors are expected to significantly boost the growth of the segment over the forecast period.
   

The nasal drug delivery technology market is segmented into nasal congestion, rhinitis, asthma, vaccination, and other applications based on application. The rhinitis segment is projected to reach USD 45 billion by 2032.
 

• The mounting incidence of rhinitis, especially allergic rhinitis, greatly increases the proportion of patients looking for effective therapeutics. For instance, according to the National Institutes of Health (NIH), allergic rhinitis is present in 10-30% of the adult population and about 40% of children across the globe, totaling over 400 million individuals. Millions of these people suffering from seasonal and perennial allergies rely on nasal delivery systems to alleviate symptoms of nasal congestion, sneezing, and itching. Such high prevalence indicates great market opportunity for drug delivery systems targeting rhinitis.
   
• The rest of the world has been slow to adopt many of these new innovations, including improved formulation techniques and device design for nasal delivery technologies such as sprays. Improved treatment outcomes are expected from innovation in controlled-release formulations and dosage precision. Advancement in these technologies will likely lead to an increase in the nasal drug delivery market.
   
• The rapid action such drug delivery systems provide is beyond commendable as the medicines are absorbed through the nasal mucosa and provide great ultimate relief from rhinitis symptoms. This is especially useful for patients who need quick relief from discomfort. Because these devices are effective at alleviating symptoms, they are more likely to be used and ultimately accepted in large numbers in this widely experienced condition.
   
• Therefore, the aforementioned factors are expected to significantly boost the growth of the segment in the coming years.
   

The nasal drug delivery technology market is segmented by distribution channel into hospital pharmacies, retail pharmacies, and e-commerce. In 2023, the retail pharmacies segment was valued at USD 37.8 billion.
 

• Nasal drug delivery systems are increasing in popularity and are readily available to patients in retail pharmacies. The OTC nature of these medications encourages self-treatment as prescription drugs often have legal restrictions.
   
• Moreover, the heightened self-medication culture and consumer's knowledge regarding the sprays and drops have also increased the demand for nasal sprays and drops. These products are distributed mainly through retail pharmacies.
   
• Most of these pharmacies also stock a variety of nasal drug delivery products like antihistamines, corticosteroids, decongestants, and saline solutions. This increase in stock may enable consumers to purchase the most relevant treatment option.
   
• Therefore, the aforementioned factors are expected to significantly boost the growth of the market over the forecast period.
   

The nasal drug delivery technology market is segmented by end use is classified into hospitals, clinics, homecare settings, and other end users. In 2023, the homecare settings segment was valued at USD 32.8 billion.
 

• Nasal drug delivery systems enhance medication compliance and patient care outcomes. The system facilitates self-administration by providing non-invasive and comfortable application of drugs. This is very important for patients suffering from chronic ailments such as asthma and allergies, which require medication over prolonged periods.
   
• The trend towards home healthcare is favorable because patients prefer a more personalized approach towards treatment. More people are now opting for self-administered therapies, and the nasal drug delivery systems are an ideal choice for such patients. This new trend towards home healthcare will command further advancements in the technologies of nasal drug delivery.
   
• The need for efficient home treatment approaches has risen on account of the growing occurrence of chronic respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD). Nose sprays and drops are easy to use and help cope with symptoms quickly while patients are at home.
   
• Furthermore, according to the World Health Organization (WHO), roughly 339 million people globally living with asthma ought to show the significance of productive nasal drug delivery systems. Moving forward as the world continues to struggle with respiratory diseases, it is inevitable that nasal drug delivery systems will be increasingly pivotal in patient care.
   
• Therefore, the aforementioned factors are expected to significantly affect the market over the coming years.
   

The U.S. nasal drug delivery technology market was valued at USD 30 billion in 2023 and is expected to grow at a CAGR of 6.9% over the forecast period.
 

• There is high incidence of allergic diseases, asthma, and other forms of respiratory illness in the U.S. Asthma and Allergy Foundation of America claims that over 28 million people in the U.S. suffer from asthma. Addressing these challenges sets the momentum for the increasing acceptance of nasal drug delivery systems, which are highly effective in providing prompt response and focused action. Considering the high figures, the significance of nasal drug delivery systems in overcoming respiratory problems remains on the rise.
   
• The country has many top pharmaceutical and biotechnology firms that devote considerable attention and money to research and development. As a result of such consideration, advanced nasal drug delivery systems, including new nasal drug formulations and devices to enhance efficacy and patient compliance, have been developed.
   
• The ongoing robust expenditure on research and development will further advance nasal drug delivery technologies and will ultimately benefit patients suffering from respiratory ailments.
   
• Therefore, the aforementioned factors are expected to boost market growth in the region over the coming years.
   

The nasal drug delivery technology market in the UK is expected to experience significant growth from 2024 to 2032.
 

• United Kingdom has in place an effective regulatory system that aids in the creation and commercialization of nasal drug delivery devices. The Medicines and Healthcare products Regulatory Agency (MHRA) disseminates information that helps in encouraging innovations while safeguarding the safety of the patients as well as the effectiveness of the product. This regulatory framework is positive for further development of nasal drug delivery devices in the UK market.
   
• In the UK, respiratory diseases, including asthma and chronic obstructive pulmonary disease (COPD), are common. Approximately 1.2 million people are projected to be suffering from COPD in the UK, as per the Scottish Government.
• According to the reports from NHS England, respiratory ailments account for the third-highest mortality rate in UK. This significant death rate adds strain to the search for effective nasal drug delivery systems that relieve and control symptoms. There is a need to maintain concentrated efforts toward the development of new technologies of nasal drug delivery in the UK due to the increasing volume of patients with respiratory ailments.
• Hence, the increasing awareness and government programs are expected to significantly boost the market growth in the region over the coming years.

The Japan nasal drug delivery technology market is anticipated to witness substantial growth between 2024 – 2032.

• In 2023, women's average life expectancy in Japan reached 87.14 years, while men's was 81.09 years, making it one of the highest in the world, according to the World Health Organization (WHO).
   
• This aging population is associated with a heightened occurrence of enduring ailments like allergies and respiratory diseases. This is also increasing the need for easy-to-use treatment such as nasal drug delivery systems among older populations.
   
• Japanese authorities are encouraging steps to enhance the availability of healthcare services and the production of new drugs and their delivery systems. Moreover, guidelines that facilitate the approval and entry into the market of advanced nose-to-brain drug delivery systems are also enhancing market growth.
   
• Therefore, the following factors are expected to bolster market growth in the region over the forecast period.
   

The nasal drug delivery technology market in Saudi Arabia is expected to experience significant growth from 2024 to 2032.
 

• Urbanization, pollution, and climate changes have all contributed to an increase in respiratory diseases, such as asthma and allergic conditions, within Saudi Arabia.
   
• In Saudi Arabia, asthma affects about 10% of the population. This is according to the Saudi Medical Journal. Moreover, WHO argues that major cities in the kingdom notoriously surpass suggested levels of air pollutants, which plays a part in breathing problems.
   
• The growing need for more efficacious treatment options for asthma and other respiratory conditions in Saudi Arabia stresses the importance for the country to develop new therapeutic modalities including drugs and their delivery systems.
   
• Therefore, the aforementioned factors are expected to boost market growth in the region over the coming years.
   

Nasal Drug Delivery Technology Market Share

The market of nasal drug delivery technology is highly fragmented due to the presence of large international corporations and smaller to medium companies competing for a share of the market. A notable portion of the market strategy centers on the constant introduction of products that apply multiple technologies. It is important to recognize that the leading companies in this industry wield a lot of power in this industry and, in many cases, provide the directions for its development due to their large investments in R&D. Moreover, strategic partnerships, mergers and acquisitions are also instrumental in achieving competitiveness and scale in response to changing market and regulatory conditions.
 

Nasal Drug Delivery Technology Market Companies

Some of the eminent market participants operating in the nasal drug delivery technology industry include:

• Aegis Therapeutics
• AptarGroup
• Boehringer Ingelheim
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• GlaxoSmithKline
• Horizon Therapeutics
• Johnson & Johnson
• Merck
• Nasal Technologies
• Neuralstem
• Pfizer
• Regeneron Pharmaceuticals
• Takeda Pharmaceutical Company
• XenoPort
   

USPs for the top market players:

• AptarGroup is a market leader in the pharmaceuticals industry, specializing in smart nasal spray technologies that allow for accurate and controlled quantity dosage.
   
• Boehringer Ingelheim apply their formulation science knowledge to develop potent corticosteroids for the treatment of asthma and chronic obstructive pulmonary diseases (COPD) to ensure the drugs work quickly with fewer side effects.
   
• F. Hoffmann-La Roche AG systems are designed with a focus on increased bioavailability and limited systemic exposure, making them ideal for the treatment of precision medicine-based therapies for cancer and other rare diseases.
   
• Pfizer is actively involved in the development of new systems and methods of associative nasal drug delivery that are user-friendly whilst improving clinical outcomes.
   

Nasal Drug Delivery Technology Market Industry News:

• In October 2024, Aero Pump and Resyca announced a partnership to launch the innovative Ultra Soft Nasal Pump Spray. The Ultra Soft Nasal Pump Spray was meant for nose-to-brain therapies and provides an innovative non-invasive approach to drug delivery to the central nervous system via the nasal cavity. This launch greatly enhanced the company's market presence.
   
• In October 2024, Aptar Pharma, a leader in drug delivery systems, announced the acquisition of all active technology from the proprietary portfolio of SipNose nasal delivery systems, a company manufacturing specialized systems for intranasal delivery of local, systemic, and central nervous system (CNS) drugs. This acquisition strengthened the company's portfolio, broadened its reach, and optimized patient treatment solutions through enhanced nasal drug devices.
   

The nasal drug delivery technology market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Sprays
• Drops and liquids
• Gels
• Powders

Market, By Container Type

• Pressurized containers
• Non-pressurized containers

Market, By Application

• Nasal congestion
• Rhinitis
• Asthma
• Vaccination
• Other applications

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• E-commerce

Market, By End Use

• Hospitals
• Clinics
• Homecare settings
• Other end users

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America 
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE